Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Lexicon Pharmaceuticals, Inc. (LXRX)

2.2300 -0.0100 (-0.45%)
At close: 4:00:00 PM EDT
2.2500 +0.0200 (+0.90%)
After hours: 4:29:04 PM EDT
Trade LXRX on Coinbase
Chart Range Bar
Loading chart for LXRX

What's happening with LXRX?

2m ago
Powered by Yahoo Scout

Lexicon Pharmaceuticals recently reported a significant Q2 revenue dropto $692,000and a $31.8 million net loss, while presenting promising data from its sotagliflozin trials. The company's future hinges on upcoming trial results and regulatory decisions, particularly for its SONATA-HCM studyexpected in Q1 2027.

Powered by Yahoo Scout
  • Previous Close 2.2400
  • Open 2.2100
  • Bid 1.9000 x 100
  • Ask 2.5700 x 100
  • Day's Range 2.1900 - 2.2500
  • 52 Week Range 1.0600 - 2.6800
  • Volume 1,566,700
  • Avg. Volume 3,350,830
  • Market Cap (intraday) 992.252M
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1600
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.86

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

www.lexpharma.com

81

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LXRX
93.91%
S&P 500 (^GSPC)
12.10%

1-Year Return

LXRX
106.48%
S&P 500 (^GSPC)
18.14%

3-Year Return

LXRX
40.25%
S&P 500 (^GSPC)
72.15%

5-Year Return

LXRX
51.84%
S&P 500 (^GSPC)
69.99%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 692k
Earnings -31.77M
Profit Margin -4,591.76%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-30M
-20M
-10M
0
10M
20M
-4000.0%
-3000.0%
-2000.0%
-1000.0%

Analyst Insights

View More

Top Analyst

HC Wainwright & Co.
49/100
Latest Rating
Buy

Analyst Price Targets

2.00
3.86 Average
2.2300 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/11/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 2.3 -> 3.1

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    1.00B

  • Enterprise Value

    872.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.27

  • Price/Book (mrq)

    5.75

  • Enterprise Value/Revenue

    21.03

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -147.38%

  • Return on Assets (ttm)

    -14.32%

  • Return on Equity (ttm)

    -40.21%

  • Revenue (ttm)

    41.47M

  • Net Income Avi to Common (ttm)

    -61.12M

  • Diluted EPS (ttm)

    -0.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    190.61M

  • Total Debt/Equity (mrq)

    33.94%

  • Levered Free Cash Flow (ttm)

    -44.77M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.2300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 10/13/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Insider Picks for 09/20/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Daily – Vickers Top Insider Picks for 09/19/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

  • Daily – Vickers Top Insider Picks for 09/18/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: